Enanta Pharmaceuticals | 销售和管理费用





销售和管理费用 更改 日
AbbVie USD 3.89B 325M 2025-12
Amgen USD 1.94B 237M 2025-12
Anika Therapeutics USD 12.91M 17.8M 2025-03
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 148M 4.86B 2025-09
BioCryst Pharmaceuticals USD 80.47M 15.39M 2024-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.35B 6M 2025-09
GlaxoSmithKline GBP 2.68B 518M 2025-12
Halozyme Therapeutics USD 37.53M 4.53M 2025-09
Heron Therapeutics USD 23.34M 4.18M 2024-09
Immunic USD -0.24 0.03 2024-09
Incyte USD 390.41M 61.33M 2025-12
Insmed USD 186.38M 109.94M 2025-09
Ionis Pharmaceuticals USD 86.56M 4.04M 2025-09
J&J USD 6.75B 831M 2025-12
Karyopharm Therapeutics USD 27.19M 442K 2024-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
Merck USD 2.85B 215M 2025-12
Neurocrine Biosciences USD 291.6M 5.3M 2025-09
Novartis USD 3.31B 134M 2025-09
Novavax USD 66.95M 34.05M 2024-09
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 84.05M 1.22M 2025-09
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
Vertex Pharmaceuticals USD 445.1M 20.5M 2025-09


Enanta Pharmaceuticals 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.